Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Unmet Need | Previously Treated, Metastatic | US/EU | 2020

While the incidence of gastric and GEJ adenocarcinoma continues to rise, efficacious treatment options, especially in the previously treated metastatic setting, remain limited. Cyramza (Eli Lilly) and cytotoxic therapies are the mainstays of treatment, and new therapies, including Keytruda (Merck & Co.) and Lonsurf (Taiho Oncology), have recently been added to the armamentarium. Several new therapies, spanning novel drug classes, are in development, and if they can demonstrate greater survival benefits than the current standards of care, they could reap significant commercial rewards. The substantial unmet need for therapeutic management of previously treated metastatic gastric and GEJ adenocarcinoma with more-efficacious and well-tolerated novel therapies presents an attractive opportunity for drug developers.

QUESTIONS ANSWERED

• What are the treatment drivers and goals for previously treated metastatic gastric and GEJ adenocarcinoma?
• What attributes are key influencers, which have limited impact, and which are hidden opportunities for drug developers?
• How do current therapies perform on key treatment drivers and goals for metastatic gastric and GEJ adenocarcinoma?
• What are the prevailing areas of unmet need and opportunity in previously treated metastatic gastric and GEJ adenocarcinoma?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 31 European medical oncologists.

Key drugs: Herceptin, Cyramza, Keytruda, Lonsurf.